FDA approves first cell therapy to treat aggressive forms of melanoma
Amtagvi is intended to help patients with melanoma that cannot be removed with surgery or has spread to other parts of the body. (Source: NPR Health and Science)
Source: NPR Health and Science - February 17, 2024 Category: Consumer Health News Authors: Juliana Kim Source Type: news
In'major milestone,' FDA approves first cell therapy for solid tumors
Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from…#iovance #allisonbetofwarner #stanforduniversity #betofwarner (Source: Reuters: Health)
Source: Reuters: Health - February 17, 2024 Category: Consumer Health News Source Type: news
Inaugural Award Poised to Advance Treatment Options for Uveal Melanoma Patients
CURE OM Team Award Earmarks a Significant Milestone for the Uveal Melanoma Population WASHINGTON , Feb. 16, 2024 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) recently announced the winners of the inaugural CURE OM Options Bring Hope Team Science Award: Bruce Ksander, PhD... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 17, 2024 Category: Pharmaceuticals Tags: AWD Source Type: news
FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma
Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that…#pd1 #braf #mek #petermarks #phd #fda #melanoma #nicoleverdun #acceleratedapproval #effectiveness (Source: Reuters: Health)
Source: Reuters: Health - February 17, 2024 Category: Consumer Health News Source Type: news
FDA Approves First Cellular Therapy for Metastatic Melanoma FDA Approves First Cellular Therapy for Metastatic Melanoma
Lifileucel is the first cellular therapy to be approved to treat patients with unresectable or metastatic melanoma.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 16, 2024 Category: Dermatology Tags: Dermatology Source Type: news
FDA OKs First Cellular Therapy for Melanoma
(MedPage Today) -- The FDA approved the cellular therapy lifileucel (Amtagvi) for the treatment of patients with previously treated unresectable or metastatic melanoma, the agency announced Friday.
Lifileucel, a cellular therapy with tumor-infiltrating... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - February 16, 2024 Category: Dermatology Source Type: news
FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 16, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Lockdown diagnosis delays caused jump in skin cancer deaths, study suggests
Research finds greater proportion of people diagnosed with more advanced melanoma since Covid restrictionsDelays in diagnosis and treatment of a dangerous type of skin cancer because of Covid lockdowns resulted in more than 100,000 years of life lost across Europe and cost the economy more than £6bn, research has suggested.While lockdowns saved lives from Covid, ramifications of the restrictionsare apparent in many areas of healthcare, from lengthy waiting lists for surgery todelays in cancer diagnoses and treatment.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - February 16, 2024 Category: Science Authors: Nicola Davis Science correspondent Tags: Skin cancer Coronavirus Health Medical research Doctors Source Type: news
Pathology Lab Shortages in New Zealand Are One Cause in Long Delays in Melanoma Diagnoses
Similar diagnostic delays due to clinical laboratory staff shortages are reported in other nations as well Critical pathology shortages are causing lengthy delays for clinical laboratory test results in New Zealand, according to a report that states some patients are waiting over a month for a melanoma diagnosis. This situation puts the lives of cancer […]
The post Pathology Lab Shortages in New Zealand Are One Cause in Long Delays in Melanoma Diagnoses appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - February 14, 2024 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: International Laboratory News Laboratory Hiring & Human Resources Laboratory Management and Operations Laboratory Resources anatomic pathology APS clinical laboratory clinical pathology Community Anatomic Pathology Service Dark Daily d Source Type: news
Smoking Linked to Melanoma-Associated Death in Early-Stage Melanoma
MONDAY, Feb. 12, 2024 -- For patients with clinical stage I and II melanoma, smoking is associated with an increased risk for melanoma-associated death, according to a study published online Feb. 6 in JAMA Network Open.
Katherine M. Jackson, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 12, 2024 Category: Pharmaceuticals Source Type: news
Periocular Melanoma Still Rare, But May Be Increasing Periocular Melanoma Still Rare, But May Be Increasing
Pain and vision loss are late symptoms of periocular melanoma, and there are amelanotic variants.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 9, 2024 Category: Cancer & Oncology Tags: Dermatology Source Type: news
Smoking Tied to Increased Mortality From Early-Stage Melanoma
(MedPage Today) -- Patients with clinically localized primary cutaneous melanoma who smoked cigarettes at the time of diagnosis had an increased risk of melanoma-associated mortality, a cohort study showed.
In a post hoc analysis of data derived... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - February 6, 2024 Category: Dermatology Source Type: news
Man told NHS will not fund £40k a time treatment
Craig Shore, who has ocular uveal melanoma, will have to pay up to £240,000 for chemosaturation. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - February 5, 2024 Category: Consumer Health News Source Type: news
Moderna cancer vaccine trial begins in UK, scientists hopeful of 'dawn of a new age of treatments'
Cancer patients in the UK are part of a global trial for the mRNA therapy mRNA-4359. The phase 1/2 clinical trial, sponsored by Moderna, aims to evaluate the safety and efficacy of the therapy in treating melanoma, lung cancer, and other solid tumor cancers. The therapy uses mRNA to train the immune system to recognize and combat cancer cells expressing common tumor markers. The trial is conducted in collaboration with Moderna-UK Strategic Partnership and aims to bring mRNA vaccine manufacturing to the UK. The first patient to receive mRNA-4359 was an 81-year-old man with treatment-resistant malignant melanoma. (Source: The Economic Times)
Source: The Economic Times - February 5, 2024 Category: Consumer Health News Source Type: news
